BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity.

Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.

April 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The FDA has approved Novartis's radioligand treatment, Lutathera®, as the initial specific drug for young patients with neuroendocrine tumors of the gastroenteropancreatic area.

The Therapeutic Index (TI) is an important parameter in assessing the safety of drugs. It is used to measure the relationship between the safety and effectiveness of a drug.

European Commission approves Astellas' XTANDI™ (Enzalutamide) for expanded use in recurrent early-stage prostate cancer treatment.

CSL Vifor and Travere Therapeutics Report European Commission's Approval of FILSPARI® (sparsentan) for IgA Nephropathy Treatment.

OncoC4 Reveals FDA Approval for Investigational New Drug Application of Its Unique SIGLEC 10 Immune Checkpoint Blocker, ONC-841, Targeting Solid Tumors.

hC Bioscience Reveals Primary Project in Hemophilia and Shares Encouraging Early Results from Innovative Protein Modification Strategy Using Engineered tRNA Anticodons.

Alto Neuroscience revealed encouraging initial outcomes for ALTO-101, a new PDE4 inhibitor, aimed at treating schizophrenia.

Hanmi Pharmaceutical will start a phase 1 clinical trial to evaluate the safety and effectiveness of its cancer immunotherapy, ‘BH3120’, in combination with MSD's KEYTRUDA® (pembrolizumab).

BeiGene, Ltd. disclosed that tislelizumab has received approval from the European Commission for use in treating non-small cell lung cancer.